Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 31.23M P/E - EPS this Y 30.50% Ern Qtrly Grth -
Income -37.94M Forward P/E -1.24 EPS next Y - 50D Avg Chg -19.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -36.00%
Dividend N/A Price/Book 0.79 EPS next 5Y - 52W High Chg -75.00%
Recommedations 2.00 Quick Ratio 2.50 Shares Outstanding 29.35M 52W Low Chg 11.00%
Insider Own 34.72% ROA -40.36% Shares Float 18.05M Beta 0.92
Inst Own 16.50% ROE -125.50% Shares Shorted/Prior 2.03M/147.27K Price 1.08
Gross Margin - Profit Margin - Avg. Volume 20,837 Target Price 11.00
Oper. Margin - Earnings Date - Volume 38,028 Change 2.86%
About Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Candel Therapeutics, Inc. News
04/25/24 Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
04/12/24 Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag
04/11/24 Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
04/09/24 Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
04/06/24 Retail investors invested in Candel Therapeutics, Inc. (NASDAQ:CADL) up 320% last week, insiders too were rewarded
04/05/24 Candel (CADL) Up on Upbeat Data From Pancreatic Cancer Study
04/04/24 After Brain Cancer Data, Candel Therapeutics' Shares Good News From Pancreatic Cancer Study
04/04/24 Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
03/28/24 Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
03/28/24 Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
03/05/24 Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
02/13/24 CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
02/05/24 Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts
12/13/23 Candel (CADL) Rises on FDA's Fast Track Status for CAN-2409
12/12/23 Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic Cancer
11/28/23 Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409
11/09/23 Candel Therapeutics Inc (CADL) Reports Q3 2023 Financial Results and Clinical Progress
11/09/23 Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
11/04/23 Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC
11/03/23 Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
CADL Chatroom

User Image IWillSucceed Posted - 22 seconds ago

$CADL heavier then normal volume, no news, who knows this market.

User Image Rodeodrive1 Posted - 40 seconds ago

$CADL Holy sh*t!!! 😃💥🚀 We are flying!

User Image hunter33 Posted - 1 minute ago

$CADL whats going on? why the move?

User Image FakeWhiteGuy Posted - 2 minutes ago

$CADL i covered guys...candle 3 complete bitches .

User Image AMATEUR_INVESTOR_ Posted - 2 minutes ago

$CADL That data is going to help us making some epic moves 💸💸💸

User Image AMATEUR_INVESTOR_ Posted - 3 minutes ago

$CADL LFG 😎

User Image skitz265 Posted - 3 minutes ago

$CADL we got some movement so cue the pumpers and bears. There goes the silence I was enjoying earlier

User Image Rounderssss4 Posted - 4 minutes ago

$CADL nsclc Data after hours would be sick

User Image FakeWhiteGuy Posted - 4 minutes ago

$CADL king told yall 771 this morning..before fool report me

User Image skitz265 Posted - 5 minutes ago

$CADL maybe I am dreaming but I am sniffing some major news coming. Don't ask me what but, something is

User Image Rounderssss4 Posted - 5 minutes ago

$CADL let's go

User Image creativeflood Posted - 5 minutes ago

$CADL back to test 11s before the positive release on the 23rd?

User Image graywolf Posted - 6 minutes ago

$CADL Release the hounds!

User Image creativeflood Posted - 7 minutes ago

$CADL breaking out

User Image Rounderssss4 Posted - 8 minutes ago

$CADL

User Image theALERTER Posted - 8 minutes ago

$CADL wanna see something interesting… watch what happens after 7.92….. do I know what’ll happen? NOPE… but it’ll be interesting 😆 All the PIPE of the top 3 cancers being effectively treated and extending life considerably is freaking GOLD. Up or down, I’m here for the long.

User Image FakeWhiteGuy Posted - 26 minutes ago

$CADL soft ass bitch got me suspended. ..just for that imma box this bitch..😆 🤣 😂

User Image MrsBelfort Posted - 41 minutes ago

$CAPR $CADL Recommend to have both in your portfolio.

User Image James_West_1965 Posted - 1 hour ago

$CADL Resistance @ $7.49. It has now hit it three times and unable to break through. Perhaps the last hour will be different. If so, it could run to $8.

User Image AMATEUR_INVESTOR_ Posted - 1 hour ago

$CADL Needs to stop teasing and just move on to 7.50+ territory 😎

User Image AMATEUR_INVESTOR_ Posted - 1 hour ago

$CADL

User Image Rounderssss4 Posted - 2 hours ago

$CADL can we get closer to 8 today if not tomorrow is ok too

User Image TideCharts13 Posted - 2 hours ago

$IBRX $CADL i can’t decide which is sexier, good thing we own both

User Image gooseandbear12 Posted - 3 hours ago

$CADL sold at 7.47 and bought back in at 7.17! Thanks 😋

User Image skitz265 Posted - 4 hours ago

$CADL am I the only one who loves the silence on this board

User Image Diefreeandsell Posted - 4 hours ago

$CADL low vol breakout! what do you know, so surprised!

User Image EmSol Posted - 4 hours ago

$CADL $10

User Image AMATEUR_INVESTOR_ Posted - 4 hours ago

$CADL A close over 7.30 will be nice 😎

User Image brunoq14 Posted - 5 hours ago

$CADL Sold for small gain. Will buy back if there's a dip before ASCO.

User Image Musti053 Posted - 5 hours ago

$CADL Dude with his $100 position is taking over the board everyone.

Analyst Ratings
HC Wainwright & Co. Buy Nov 13, 23
HC Wainwright & Co. Buy May 22, 23
BMO Capital Outperform May 15, 23
Credit Suisse Outperform Mar 31, 23
Credit Suisse Outperform Dec 7, 22
HC Wainwright & Co. Buy Dec 2, 22
BMO Capital Outperform Mar 31, 22
BMO Capital Outperform Nov 19, 21
UBS Buy Aug 23, 21
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Aguilar Laura K. 10% Owner 10% Owner May 06 Option 1.46 171,335 250,149 1,102,374 05/10/22
Aguilar-Cordova Estuardo Director Director May 06 Option 1.46 135,183 197,367 1,151,106 05/10/22